In today’s dynamic Pharma and Life Sciences environment, AI has the potential to be a powerful driver of innovation, efficiency, and improved patient outcomes. But while investment is high, many organisations are yet to translate that promise into real-world value.
At Baringa, we’ve worked with pharma companies to unlock the true value of AI focussing on four key areas: getting data right, implementing appropriate governance, embedding organisational trust and upskilling teams to drive adoption.
Without the right foundations in place, companies risk AI remaining a siloed experiment rather than a strategic enabler. Our experts can help you navigate this transformation, ensuring AI delivers measurable value across your enterprise -scientifically, commercially, and for patients.
Unlocking the business value from AI in Pharma
Artificial Intelligence (AI) holds tremendous promise across the pharmaceutical and life sciences industry. Estimates suggest that, if scaled effectively, AI could generate up to $254 billion in additional annual operating profits for pharma companies globally by 2030. Explore four areas where life sciences companies frequently fall short – and outline the critical enablers to achieving both scale and value from AI investments.
Our Experts
Is digital and AI delivering what your business needs?
Digital and AI can solve your toughest challenges and elevate your business performance. But success isn’t always straightforward. Where can you unlock opportunity? And what does it take to set the foundation for lasting success?